Edition:
United Kingdom

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

16.57USD
6:18pm GMT
Change (% chg)

$-0.49 (-2.87%)
Prev Close
$17.06
Open
$17.20
Day's High
$17.48
Day's Low
$16.57
Volume
54,134
Avg. Vol
115,745
52-wk High
$19.75
52-wk Low
$4.93

Summary

Name Age Since Current Position

Edward Mathers

58 2010 Independent Chairman of the Board

Douglas Treco

60 President, Chief Executive Officer, Co-Founder, Director

David Lubner

54 2016 Chief Financial Officer, Executive Vice President

Simon Read

47 2016 Chief Scientific Officer

Ramin Farzaneh-Far

40 2016 Chief Medical Officer

John King

43 2018 Chief Commercial Officer

Aoife Brennan

2018 Director

Peter Bisgaard

44 2015 Independent Director

Robert Heft

63 2016 Independent Director

Timothy Pearson

50 2016 Independent Director

Rajeev Shah

41 2015 Independent Director

Natalie Wildenradt

2017 IR Contact Officer

Biographies

Name Description

Edward Mathers

Mr. Edward T. Mathers is a Independent Chairman of the Board of Ra Pharmaceuticals, Inc. Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO). Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Douglas Treco

Dr. Douglas (Doug) A. Treco, Ph.D. is the Co-Founder, President and Chief Executive Officer, Member of the Board of Directors of Ra Pharmaceuticals Inc. Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc),a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his PhD in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.

David Lubner

Mr. David Charles Lubner serves as Executive Vice President and Chief Financial Officer of the company since January 2016. Before joining our company, Mr. Lubner served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. ("Tetraphase"), a biotechnology company, from its inception in 2006 through 2015. From 2010 to 2015, Mr. Lubner served as Senior Vice President and the Chief Financial Officer of Tetraphase, where he led financial operations and was responsible for corporate finance activities. From 1999 to 2005, he served as the Chief Financial Officer of PharMetrics Inc., a pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc. from 1996 to 1999. Mr. Lubner is also a member of the board of directors of Nightstar Therapeutics plc. Mr. Lubner is a member of the American Institute of CPAs and a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Lubner received his B.S. in business administration from Northeastern University and M.S. in taxation from Bentley University.

Simon Read

Dr. Simon Read, Ph.D. serves as Chief Scientific Officer of the company since April 2016. Prior to joining our company, Dr. Read served as a Vice President, Head of the Innovative Medicines Unit and Head of Global Biomedical Sciences at Grunenthal GmbH, a pharmaceutical company headquartered in Aachen, Germany, from 2011 to March 2016. Before joining Grunenthal, Dr. Read was the Director, Experimental Medicine and Biomarkers, Immunology with Roche Products / Genentech Inc. from 2008 to 2011. Dr. Read has been a member of the Medical Research Council and Association of British Pharmaceutical Industry Steering Committee for the U.K.'s Immunology Consortium since 2012. Dr. Read is an elected fellow of the Royal Society of Medicine and the Royal Society of Biology in the U.K. since 2017 and a member of the Boston Children's Hospital Technology Development Fund steering group since 2016. Dr. Read received his B.Sc. in Physiology from University of Manchester, M.Sc. from University of Southampton and Ph.D. from University of Hertfordshire.

Ramin Farzaneh-Far

Dr. Ramin Farzaneh-Far, M.D. serves as Chief Medical Officer of the company since July 2016. Before joining the company, from 2015 to 2016, he served as the Vice President of Medical Research at Akebia Therapeutics, Inc. From 2012 until he joined Akebia, Dr. Farzaneh-Far served as the Director of Clinical Research at Gilead Sciences, Inc., where he led the clinical development of multiple assets in the cardiovascular therapeutic area. Dr. Farzaneh-Far held various academic faculty positions at the University of California, San Francisco, or UCSF, and the University of Texas Southwestern Medical Center from 2009 to 2012. He completed his internal medicine residency at Brigham & Women's Hospital in Boston, and trained in cardiovascular medicine at UCSF. Dr. Farzaneh-Far received his B.A. and M.A. degrees in immunology from the University of Cambridge, his M.D. from University College London, and his MAS in Clinical Research from UCSF

John King

Mr. John C. King serves as Chief Commercial Officer of the company since April 2018. Before joining our company, Mr. King served as a member of the senior management team of Alexion Pharmaceuticals, Inc. ("Alexion"), a global biopharmaceutical company, from 2009 through March 2018. From 2017 to 2018, Mr. King served as Vice President, U.S. Neurology Business Unit. In this role, he was responsible for building and leading the team launching Soliris® (eculizumab) for gMG in the U.S. At Alexion, he also served as Vice President, Head of Global LAL-D Franchise from 2015 to 2017, Vice President, Head of Global PNH Franchise from 2014 to 2015 and Executive Director, Global Hematology Marketing from 2012 to 2013. Prior to joining Alexion, Mr. King served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals. He began his career at Ernst & Young LLP. Mr. King obtained his B.S. in business logistics and labor relations and his MBA in finance and management from Pennsylvania State University.

Aoife Brennan

Peter Bisgaard

Mr. Peter Tuxen Bisgaard serves as Independent Director of the company since 2015. Mr. Bisgaard is currently the Managing Director of NF Life Sciences, a global health care and life sciences investment firm. From 2009 to August 2017, Mr. Bisgaard was previously employed as a partner of Novo Ventures (US), Inc., which provides consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets. He is currently a member of the board of directors of private companies Eargo, Inc. and Chromaderm, Inc. He is a past member of the board of directors of a number of public companies, including Nevro Corp., Alder Biopharmaceuticals, Inc., Otonomy, Inc., and HTG Molecular Diagnostics, Inc., and past member of the board for a number of private companies including Inozyme Pharma, LLC, Bolt Therapeutics, Inc., and Entasis Therapeutics. Mr. Bisgaard obtained his M.Sc. in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in mathematical modeling in economics by the European Consortium for Mathematics in the Industry.

Robert Heft

Dr. Robert Heft, Ph.D. serves as Independent Director of the company since March 2016. Dr. Heft currently serves as Chief Executive Officer of Zingenix Ltd., a company focused on gene therapy for severe orphan disorders. Prior to joining Zingenix in 2014, Dr. Heft was Chief Executive Officer and a member of the board of directors of Enobia Pharma Inc. from 2005 to 2012. Dr. Heft currently serves on the boards of Parvous Therapeutics Inc., Zingenix Ltd., VisionGate, Inc., Lumos Pharma Inc., and Clementia Pharmaceuticals, Inc. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft obtained his Ph.D. from the Massachusetts Institute of Technology in genetic engineering and radiological sciences, as well as a Master of Engineering Degree from Cornell University and a Bachelor of Engineering Degree from McGill University.

Timothy Pearson

Mr. Timothy R. Pearson serves as independent Director of the company since March 2016. Mr. Pearson currently serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, Mr. Pearson served as Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc. from August 2011 to July 2012, where he led the finance and strategic planning functions. Prior to that, Mr. Pearson was Executive Vice President and Chief Financial Officer of MedImmune, the biologics division of AstraZeneca. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College

Rajeev Shah

Mr. Rajeev Shah serves as independent Director of the company since July 2015. Mr. Shah has been a portfolio manager and managing director at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies since 2004. Mr. Shah is also a member of the board of directors of Kala Pharmaceuticals, Inc. and Solid Biosciences Inc. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals from 2015 through April 2018. Mr. Shah received a B.A. in Chemistry from Cornell University.

Natalie Wildenradt

Basic Compensation

Name Fiscal Year Total

Edward Mathers

290,324

Douglas Treco

3,104,540

David Lubner

1,719,570

Simon Read

--

Ramin Farzaneh-Far

1,459,910

John King

--

Aoife Brennan

--

Peter Bisgaard

131,679

Robert Heft

262,824

Timothy Pearson

277,824

Rajeev Shah

269,074

Natalie Wildenradt

--
As Of  31 Dec 2017